Therapeutic Vaccines

Global Therapeutic Vaccines Market to Reach US$117.1 Billion by 2030

The global market for Therapeutic Vaccines estimated at US$46.4 Billion in the year 2024, is expected to reach US$117.1 Billion by 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Autoimmune Disease Vaccines, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$62.8 Billion by the end of the analysis period. Growth in the Neurological Disease Vaccines segment is estimated at 17.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.1 Billion While China is Forecast to Grow at 21.9% CAGR

The Therapeutic Vaccines market in the U.S. is estimated at US$12.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$29.2 Billion by the year 2030 trailing a CAGR of 21.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.2% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.0% CAGR.

Global Therapeutic Vaccines Market - Key Trends and Drivers Summarized

Why Are Therapeutic Vaccines Garnering So Much Attention?

Therapeutic vaccines, designed to treat existing diseases by stimulating the immune system to fight off illness, have become a cornerstone in modern medicine. Unlike traditional vaccines that focus on preventing infections, therapeutic vaccines target ongoing diseases such as cancer, chronic infections, and autoimmune disorders. The increasing prevalence of cancer and the growing interest in immunotherapy as a viable treatment option are key drivers in this market. Therapeutic vaccines hold the promise of revolutionizing treatment for patients who have not responded to conventional therapies, making this a highly dynamic and rapidly growing segment within the broader vaccine market.

How Are the Various Segments of the Therapeutic Vaccines Market Expanding?

Notable segments include vaccines targeting infectious diseases like HIV and hepatitis, as well as autoimmune disorders. Technology plays a crucial role in the development of these vaccines, with advances in mRNA, dendritic cell-based vaccines, and viral vectors driving significant progress. The end-user segments primarily include hospitals, cancer treatment centers, and research institutions, which are playing an instrumental role in conducting clinical trials and early-phase research on novel therapeutic vaccines.

What Technological and Regulatory Trends Are Shaping the Market?

The therapeutic vaccine market has been greatly influenced by innovations in biotechnology, particularly with the rise of personalized medicine and next-generation sequencing. Advances in understanding the immune system and tumor biology have led to the development of vaccines that are highly specific to individual patients, driving the market’s growth. Additionally, regulatory approvals for cancer vaccines, such as those targeting HPV and prostate cancer, have opened the door for further innovation in the field. Another key trend is the increasing collaboration between pharmaceutical companies and academic research institutes to accelerate vaccine development. Government initiatives and funding to support vaccine research are also providing a strong foundation for market growth.

What Are the Key Factors Driving Growth in the Therapeutic Vaccines Market?

The growth in the therapeutic vaccines market is driven by several factors, including the rising incidence of cancer and chronic infectious diseases, advancements in vaccine development technologies, and the growing number of clinical trials for therapeutic vaccines. Increased investments from pharmaceutical companies in R&D and the expansion of vaccine manufacturing infrastructure are critical drivers of market growth. Additionally, rising public awareness of immunotherapy and its potential benefits is fueling demand for therapeutic vaccines. Regulatory support in the form of fast-tracking approvals and orphan drug status for certain therapeutic vaccines is also contributing to market expansion. Finally, the global push for more effective cancer treatments is propelling significant growth in this market, especially as personalized vaccines gain traction.

SCOPE OF STUDY:

The report analyzes the Therapeutic Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Infectious Disease Vaccines, Addiction Vaccines)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 13 Featured) -

• Agenus, Inc.
• Bavarian Nordic A/S
• CEL-SCI Corporation
• Dendreon Corporation
• GlaxoSmithKline PLC
• Novartis International AG
• Oncothyreon, Inc.
• TVAX Biomedical Inc.
• Vical, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more